The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations

详细信息    查看全文

• 作者：Jessica L. Geiger^a ; Jennifer R. Grandis^b ; Julie E. Bauman^a ; ^{baumanje@upmc.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：STAT3 ; Head and neck cancer
• 刊名：Oral Oncology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：56
• 期：Complete
• 页码：84-92
• 全文大小：609 K

文摘

Proteins of the signal transducer and activator of transcription (STAT) family mediate cellular responses to cytokines and growth factors. Aberrant regulation of the STAT3 oncogene contributes to tumor formation and progression in many cancers, including head and neck squamous cell carcinoma (HNSCC), where hyperactivation of STAT3 is implicated in both treatment resistance and immune escape. There are no oncogenic gain-of-function mutations in HNSCC. Rather, aberrant STAT3 signaling is primarily driven by upstream growth factor receptors, such as Janus kinase (JAK) and epidermal growth factor receptor (EGFR). Moreover, genomic silencing of select protein tyrosine phosphatase receptors (PTPRs), tumor suppressors that dephosphorylate STAT3, may lead to prolonged phosphorylation and activation of STAT3. This review will summarize current knowledge of the STAT3 pathway and its contribution to HNSCC growth, survival, and resistance to standard therapies, and discuss STAT3-targeting agents in various phases of clinical development.